The future of CpG immunotherapy in cancer

Immunotherapy

Volumn 5, Issue 1, 2013, Pages 1-3

  Badie, Behnam ^a   Berlin, Jacob M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

CpG; nanoparticles

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ALPHA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; GOLD NANOPARTICLE; INTERLEUKIN 6; LIPOSOME; NANOPARTICLE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; POLYGLACTIN; SINGLE WALLED NANOTUBE; TOLL LIKE RECEPTOR 9;

CANCER IMMUNOTHERAPY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENDOCYTOSIS; GLIOBLASTOMA; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; LYSOSOME; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PRIORITY JOURNAL; REVIEW; SEPSIS;

HUMANS; IMMUNOTHERAPY; NANOPARTICLES; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES;

EID: 84871541224     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.148     Document Type: Review

References (16)

1. Cornelie S, Hoebeke J, Schacht AM et al. Direct evidence that Toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition. J. Biol. Chem. 279(15), 15124-15129 (2004).
2. Ursu R, Carpentier AF. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma. Adv. Exp. Med. Biol. 746, 95-108 (2012).
3. Carpentier A, Metellus P, Ursu R. et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: A Phase II study. Neuro. Oncol. 12(4), 401-408 (2010).
4. US FDA. Draft Guidance for Industry; Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology. US FDA, Silver Spring, MD, USA (2011).
5. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5(4), 487-495 (2008).
6. Suzuki Y, Wakita D, Chamoto K. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res. 64(23), 8754-8760 (2004).
7. Rattanakiat S, Nishikawa M, Takakura Y et al. Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation. Eur. J. Pharm. Sci. 47(2), 352-358 (2012).
8. Wei M, Chen N, Li J et al. Polyvalent immunostimulatory nanoagents with self-assembled CpG oligonucleotide-conjugated gold nanoparticles. Angew. Chem. Int. Ed. Engl. 51(5), 1202-1206 (2012).
9. Demento SL, Bonafe N, Cui W et al. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J. Immunol. 185(5), 2989-2997 (2010).
10. Zhao D, Alizadeh D, Zhang L et al. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin. Cancer Res. 17(4), 771-782 (2011).
11. Fan H, Zhang I, Chen X et al. Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice. Clin. Cancer Res. 18(20), 5628-5638 (2012).
12. Yasuda K, Rutz M, Schlatter B et al. CpG motif-independent activation of TLR9 upon endosomal translocation of 'natural' phosphodiester DNA. Eur. J. Immunol. 36(2), 431-436 (2006).
13. Chinnathambi S, Chen S, Ganesan S, Hanagata N. Binding mode of CpG oligodeoxynucleotides to nanoparticles regulates bifurcated cytokine induction via Toll-like receptor 9. Sci. Rep. 2, 534 (2012).
14. Tsai CY, Lu SL, Hu CW, Yeh CS, Lee GB, Lei HY. Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages. J. Immunol. 188(1), 68-76 (2012).
15. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522), 546-549 (1995).
16. Kortylewski M, Swiderski P, Herrmann A et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 27(10), 925-932 (2009).